Nyxoah (NASDAQ:NYXH – Free Report) had its price objective trimmed by Oppenheimer from $15.00 to $13.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.
A number of other research firms have also weighed in on NYXH. HC Wainwright reissued a buy rating and set a $18.00 price objective on shares of Nyxoah in a research note on Wednesday. Stifel Nicolaus reduced their price target on Nyxoah from $27.00 to $19.00 and set a buy rating on the stock in a report on Monday, June 24th. Finally, Cantor Fitzgerald dropped their price objective on shares of Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a report on Wednesday, May 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nyxoah has an average rating of Buy and a consensus price target of $17.20.
Get Our Latest Stock Analysis on Nyxoah
Nyxoah Stock Performance
Nyxoah (NASDAQ:NYXH – Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.45). The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.20 million. Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. On average, sell-side analysts forecast that Nyxoah will post -1.72 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Nyxoah
A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH – Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 50,699 shares of the company’s stock, valued at approximately $684,000.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
See Also
- Five stocks we like better than Nyxoah
- Best Stocks Under $10.00
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.